InflaRx NV (STU:IF0)
€ 2.022 0 (0%) Market Cap: 141.14 Mil Enterprise Value: 84.15 Mil PE Ratio: 0 PB Ratio: 2.04 GF Score: 38/100

InflaRx NV Virtual R&D Event Transcript

Feb 03, 2022 / 01:30PM GMT
Release Date Price: €2.91 (-5.83%)
Jordan Zwick
InflaRx N.V. - Chief Strategy Officer

Hello, thank you for joining us at our virtual R&D event, where we will discuss our Phase III program for vilobelimab, including our new primary endpoint called the modified HiSCR. A replay will also be available on our website following the live event.

Before I begin, I'd like to point out that we'll be making forward-looking statements that are based on our current expectations and beliefs. These beliefs are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for more details.

Today, our agenda will include an introduction by Niels, and HS disease overview presented by our special guest, Dr. Chris Sayed, review of vilobelimab and the mechanism of action, review of our Phase IIb SHINE study, along with key learnings. And finally, what we're all waiting for is our new Phase III program with the primary endpoint called modified HiSCR along with additional data post hoc from our SHINE study. We will also conclude the event

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot